Dendritcellebaserede cancervacciner--klinisk anvendelse.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Dendritcellebaserede cancervacciner--klinisk anvendelse. / Svane, Inge Marie; Berntsen, Annika; Trepiakas, Redas; Pedersen, Anders Elm.

I: Ugeskrift for læger, Bind 168, Nr. 14, 2006, s. 1415-20.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Svane, IM, Berntsen, A, Trepiakas, R & Pedersen, AE 2006, 'Dendritcellebaserede cancervacciner--klinisk anvendelse.', Ugeskrift for læger, bind 168, nr. 14, s. 1415-20.

APA

Svane, I. M., Berntsen, A., Trepiakas, R., & Pedersen, A. E. (2006). Dendritcellebaserede cancervacciner--klinisk anvendelse. Ugeskrift for læger, 168(14), 1415-20.

Vancouver

Svane IM, Berntsen A, Trepiakas R, Pedersen AE. Dendritcellebaserede cancervacciner--klinisk anvendelse. Ugeskrift for læger. 2006;168(14):1415-20.

Author

Svane, Inge Marie ; Berntsen, Annika ; Trepiakas, Redas ; Pedersen, Anders Elm. / Dendritcellebaserede cancervacciner--klinisk anvendelse. I: Ugeskrift for læger. 2006 ; Bind 168, Nr. 14. s. 1415-20.

Bibtex

@article{ab3a6340ac0411ddb5e9000ea68e967b,
title = "Dendritcellebaserede cancervacciner--klinisk anvendelse.",
abstract = "Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach. Udgivelsesdato: 2006-Apr-3",
author = "Svane, {Inge Marie} and Annika Berntsen and Redas Trepiakas and Pedersen, {Anders Elm}",
note = "Keywords: Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Female; Humans; Lymphocyte Activation; Male; Neoplasms; T-Lymphocytes; Treatment Outcome",
year = "2006",
language = "Dansk",
volume = "168",
pages = "1415--20",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "14",

}

RIS

TY - JOUR

T1 - Dendritcellebaserede cancervacciner--klinisk anvendelse.

AU - Svane, Inge Marie

AU - Berntsen, Annika

AU - Trepiakas, Redas

AU - Pedersen, Anders Elm

N1 - Keywords: Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Female; Humans; Lymphocyte Activation; Male; Neoplasms; T-Lymphocytes; Treatment Outcome

PY - 2006

Y1 - 2006

N2 - Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach. Udgivelsesdato: 2006-Apr-3

AB - Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach. Udgivelsesdato: 2006-Apr-3

M3 - Tidsskriftartikel

C2 - 16584668

VL - 168

SP - 1415

EP - 1420

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 14

ER -

ID: 8442899